Summary and Discussion for “Statistical Issues in the Pharmaceutical Industry: Analysis and Reporting of Phase III Clinical Trials Including Kinetic/Dynamic Analysis and Bayesian Analysis”

Sanathanan L. Random effects modeling in population: Kinetic/dynamic analysis. Drug Inf J. 1991;25: 307–317.

Swets JA . Measuring the accuracy of diagnostic systems. Science, 1988;240: 1285–1293.

Begg CB McNeil BJ . Assessment of radiologic tests: Control of bias and other design considerations. Radiology, 1988;167: 565–569.

Berry DA . Bayesian methods in Phase III trials. Drug Info J. 1991;25: 345–368.

Gould AL . Using prior findings to augment active-controlled trials and trials with small placebo groups. Drug Info J. 1991;25: 369–380.

Hughes MD . Practical reporting of Bayesian analyses of clinical trials. Drug Info J. 1991;25: 381–393.

Koch GG Gillings DB . Inference, design based vs. model based. In: Johnson N.L. Kotz S. eds. Encyclopedia of Statistical Sciences. 4. New York, Wiley;1983;84–88.

Koch GG Carr GJ Amara IA Stokes ME Uryniak TJ . Categorical data analysis. In: Berry DA . ed. Statistical Methodology in the Pharmaceutical Sciences. New York: Marcel Dekker; 1990: 389–473.

Feder PI Olson CT Hobson DW Matthews MC Joiner RL . Statistical analysis of dose response experiments by maximum likelihood analysis and iteratively reweighted nonlinear least squares regression techniques. Drug Info J. 1991;25: 323–334.

Ward JF Nardi RV . Using early drug development data to design Phase III trials. Drug Info J. 1991;25: 335–344.

Skinner JB . On combining studies. Drug Info J. 1991;25: 395–403.

Stewart WH Hafner KB . Statistical analysis of trough/peak ratios. Drug Info J. 1991;25: 405–409.